Evidence map›Paper›PMID 42734838›Full record

ArticleAnnals of hematology2026

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Anush A Ginosyan, Karam Ashouri, Justin Cheng, Lauren Ford, Mihir Baya, Lucas Humayun, Danielle Hong, Elaine Huang, Grace Kim, Brandon Tang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anush A GinosyanKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Karam AshouriKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Justin ChengKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Lauren FordKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Mihir BayaKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Lucas HumayunKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Danielle HongKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Elaine HuangKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Grace KimKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Brandon TangKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Brian HomKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert IrelandKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Imran SiddiqiDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Amir AliDepartment of Pharmacy, Norris Comprehensive Cancer Center, University of Southern California (USC), Los Angeles, CA, USA.
Karrune WoanJane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Eric Leon TamJane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
George YaghmourJane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. George.yaghmour@med.usc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The addition of venetoclax to hypomethylating agents (HMAs) is standard for older adults with newly diagnosed acute myeloid leukemia (AML). However, prolonged venetoclax (VEN) exposure can cause cytopenias and infections, raising questions about optimal duration. We conducted a single‑center retrospective study of 102 patients treated between 2018 and 2025 with azacitidine or decitabine plus VEN administered for 14 (n = 22), 21 (n = 48), or 28 (n = 32) days per 28‑day cycle. Baseline cytogenetic and molecular profiling, responses by 2022/2024 ELN criteria, measurable residual disease (MRD), cumulative incidence of relapse (CIR), disease‑free survival (DFS), and overall survival (OS) were analyzed using competing‑risks regression and Cox models. Median age was 68 years and patients received a median of 4 cycles. Composite remission (CR/CRi/CRh/MLFS) was 66.7%, with MRD negativity in 75.0% of responders. Remission and MRD negativity rates did not differ significantly across VEN‑duration cohorts. Median OS and DFS were 17.3 and 12.3 months, respectively, with no significant differences in OS, DFS, and CIR between 14‑, 21‑, and 28‑day cohorts. Grade ≥ 3 cytopenias and transfusion independence rates also did not differ significantly. In this cohort, shortening VEN exposure to 14 or 21 days did not show a significant difference in response, survival, relapse risk, and toxicity profiles relative to a 28‑day schedule in our cohort. These findings support further prospective evaluation of reduced VEN durations in this population.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesAgedAged, 80 and overAzacitidineDecitabineDisease-Free SurvivalFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineSulfonamidesvenetoclaxAMLElderlyHypomethylating agentsSurvival outcomesTreatment durationVenetoclax

Identifiers

PMID42734838
PMCPMC13574922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.